Octreotide for the Treatment of Hypercalcemia Related to B Cell Lymphoma

R. Raffaele Pezzilli
P. Paola Btili
B. Bahjat Barakat
P. Pierluigi Broccoli

Emergency Department, Sant’Orsola Hospital, Bologna, Italy
Raffaele Pezzilli, MD, Medicina d’Urgenza e Pronto Soccorso, Ospedale Sant’Orsola, Via Massarenti 9, 1-40138 Bologna (Italy)
10 9

; Steroids:
Fluids + Furosemide + Diphosphonates

Dear Sir,
Severe hypercalcemia represents a life-threatening emergency and its management is still difficult. Patients with generally have a poor outcome [1]. The fluids, diuretics, steroids, diphosphonates, and calcitonin are the most common therapeutic options. We report the case of a patient with whom all the above-mentioned serum calcium level. It was then somatostatin analogue octreotide.

A 76-year-old woman with peripheral large-cell type B lymphoma [3] was admitted to our emergency department examinations revealed severe normal values 2.1-2.8), hypophosphatemia and hemolytic anemia. Plasma PTH was undetectable (< 10 pg/ml, normal range 10-70 pg/ml). The administration of large amounts of fluids (6,000 ml/day), furo-semide, steroids and diphosphonates at the optimal doses currently suggested was started intravenously; anemia was corrected with blood transfusions. In the following 24 h, no significant changes in consciousness and serum calcium levels (4.1 mmol/l) were observed. Calcitonin (Calcitonina, Sandoz Prodotti Farmaceutici, Milan, Italy) at the dose of 24 IU/kg/24 h was added intravenously (fig. 1) and on the 4th day following admission, for persistent hypercalcemia.

Octreotide
2 7
Hemodialysis

"6 -
Octreotide
3 -
2-

Days
Fig. 1. Daily serum calcium determination. The horizontal solid line represents the upper normal limit.

days, serum calcium level progressively returned to levels within the normal range, and the patient became conscious. Nine days after the treatment was started, octreotide was stopped. Five days thereafter, serum calcium levels were again increased (over the upper normal limit; 2.9 mg/dl) and the administration of octreotide, at the same dose pre-

(4.8 mmol/l), hemodialysis was carried out without any improvement in the electrolyte alteration (serum calcium concentration: 4.4 mmol/l). On the 5th day from admission, calcitonin was stopped, and octreotide (San-dostatina, Sandoz Prodotti Farmaceutici), at a dose of 0.1 mg ter in die subcutaneously, was added to the therapy. In the following days,

KAHGEH
E-Mail karger@karger.ch Fax + 41 61 306 12 34 http://www.karger.ch
© 1997 S. Karger AG, Basel 0030-2414/97/0546-0517$ 15.00/0
This article is also accessible online at: http://BioMedNet.com/karger

It has been reported that hematological malignancies may produce PTH-like substances determining hypercalcemia [4], which could be detected in about 15 % of the patients with non-Hodgkin lymphoma [5].

Octreotide, a potent long-acting somatostatin analogue that suppresses the action of various hormones, probably determined a block of the action of PTH-like substances released by the tumor, causing a decrease in serum calcium level. The efficacy of octreotide in the treatment of hypercalcemia was confirmed by the fact that when hypercalcemia reappeared the drug was once more effective to decrease serum calcium level.

As far as we know, this is the first reported case of a patient with hypercalcemia related to B cell lymphoma in whom treatment with octreotide had beneficial effects on electrolyte alteration. Octreotide may represent a new therapeutic option in the treatment of patients with hypercalcemia in whom this condition may be due to the release of PTH-like peptides.

References

Oncology 1997;54:517-518
Pezzilli/Billi/Barakat/Broccoli